248 related articles for article (PubMed ID: 17441692)
1. Mutagenesis of p38alpha MAP kinase establishes key roles of Phe169 in function and structural dynamics and reveals a novel DFG-OUT state.
Bukhtiyarova M; Karpusas M; Northrop K; Namboodiri HV; Springman EB
Biochemistry; 2007 May; 46(19):5687-96. PubMed ID: 17441692
[TBL] [Abstract][Full Text] [Related]
2. Insights into MAPK p38alpha DFG flip mechanism by accelerated molecular dynamics.
Filomia F; De Rienzo F; Menziani MC
Bioorg Med Chem; 2010 Sep; 18(18):6805-12. PubMed ID: 20724167
[TBL] [Abstract][Full Text] [Related]
3. Human p38α mitogen-activated protein kinase in the Asp168-Phe169-Gly170-in (DFG-in) state can bind allosteric inhibitor Doramapimod.
Suplatov D; Kopylov K; Sharapova Y; Švedas V
J Biomol Struct Dyn; 2019 May; 37(8):2049-2060. PubMed ID: 29749295
[TBL] [Abstract][Full Text] [Related]
4. Improved expression, purification, and crystallization of p38alpha MAP kinase.
Bukhtiyarova M; Northrop K; Chai X; Casper D; Karpusas M; Springman E
Protein Expr Purif; 2004 Sep; 37(1):154-61. PubMed ID: 15294293
[TBL] [Abstract][Full Text] [Related]
5. Structural basis for the high-affinity binding of pyrrolotriazine inhibitors of p38 MAP kinase.
Sack JS; Kish KF; Pokross M; Xie D; Duke GJ; Tredup JA; Kiefer SE; Newitt JA
Acta Crystallogr D Biol Crystallogr; 2008 Jul; D64(Pt 7):705-10. PubMed ID: 18566506
[TBL] [Abstract][Full Text] [Related]
6. Active mutants of the TCR-mediated p38α alternative activation site show changes in the phosphorylation lip and DEF site formation.
Tzarum N; Diskin R; Engelberg D; Livnah O
J Mol Biol; 2011 Feb; 405(5):1154-69. PubMed ID: 21146537
[TBL] [Abstract][Full Text] [Related]
7. Prevention of MKK6-dependent activation by binding to p38alpha MAP kinase.
Sullivan JE; Holdgate GA; Campbell D; Timms D; Gerhardt S; Breed J; Breeze AL; Bermingham A; Pauptit RA; Norman RA; Embrey KJ; Read J; VanScyoc WS; Ward WH
Biochemistry; 2005 Dec; 44(50):16475-90. PubMed ID: 16342939
[TBL] [Abstract][Full Text] [Related]
8. High-throughput screening to identify inhibitors which stabilize inactive kinase conformations in p38alpha.
Simard JR; Grütter C; Pawar V; Aust B; Wolf A; Rabiller M; Wulfert S; Robubi A; Klüter S; Ottmann C; Rauh D
J Am Chem Soc; 2009 Dec; 131(51):18478-88. PubMed ID: 19950957
[TBL] [Abstract][Full Text] [Related]
9. The third conformation of p38α MAP kinase observed in phosphorylated p38α and in solution.
Akella R; Min X; Wu Q; Gardner KH; Goldsmith EJ
Structure; 2010 Dec; 18(12):1571-8. PubMed ID: 21134636
[TBL] [Abstract][Full Text] [Related]
10. Computational sampling of a cryptic drug binding site in a protein receptor: explicit solvent molecular dynamics and inhibitor docking to p38 MAP kinase.
Frembgen-Kesner T; Elcock AH
J Mol Biol; 2006 May; 359(1):202-14. PubMed ID: 16616932
[TBL] [Abstract][Full Text] [Related]
11. Molecular dynamics simulation and free energy calculation studies of the binding mechanism of allosteric inhibitors with p38α MAP kinase.
Yang Y; Shen Y; Liu H; Yao X
J Chem Inf Model; 2011 Dec; 51(12):3235-46. PubMed ID: 22097958
[TBL] [Abstract][Full Text] [Related]
12. Enhanced selectivity profile of pyrazole-urea based DFG-out p38alpha inhibitors.
Liu H; Kuhn C; Feru F; Jacques SL; Deshmukh GD; Ye P; Rennie GR; Johnson T; Kazmirski S; Low S; Coli R; Ding YH; Cheng AC; Tecle H; English JM; Stanton R; Wu JC
Bioorg Med Chem Lett; 2010 Aug; 20(16):4885-91. PubMed ID: 20620059
[TBL] [Abstract][Full Text] [Related]
13. High-resolution diffracting crystals of intrinsically active p38alpha MAP kinase: a case study for low-throughput approaches.
Diskin R; Engelberg D; Livnah O
Acta Crystallogr D Biol Crystallogr; 2007 Feb; 63(Pt 2):260-5. PubMed ID: 17242519
[TBL] [Abstract][Full Text] [Related]
14. The three-dimensional structure of MAP kinase p38beta: different features of the ATP-binding site in p38beta compared with p38alpha.
Patel SB; Cameron PM; O'Keefe SJ; Frantz-Wattley B; Thompson J; O'Neill EA; Tennis T; Liu L; Becker JW; Scapin G
Acta Crystallogr D Biol Crystallogr; 2009 Aug; 65(Pt 8):777-85. PubMed ID: 19622861
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation.
Gill AL; Frederickson M; Cleasby A; Woodhead SJ; Carr MG; Woodhead AJ; Walker MT; Congreve MS; Devine LA; Tisi D; O'Reilly M; Seavers LC; Davis DJ; Curry J; Anthony R; Padova A; Murray CW; Carr RA; Jhoti H
J Med Chem; 2005 Jan; 48(2):414-26. PubMed ID: 15658855
[TBL] [Abstract][Full Text] [Related]
16. Lipid molecules induce p38α activation via a novel molecular switch.
Tzarum N; Eisenberg-Domovich Y; Gills JJ; Dennis PA; Livnah O
J Mol Biol; 2012 Dec; 424(5):339-53. PubMed ID: 23079240
[TBL] [Abstract][Full Text] [Related]
17. Increased folding stability of TEM-1 beta-lactamase by in vitro selection.
Kather I; Jakob RP; Dobbek H; Schmid FX
J Mol Biol; 2008 Oct; 383(1):238-51. PubMed ID: 18706424
[TBL] [Abstract][Full Text] [Related]
18. 5-amino-pyrazoles as potent and selective p38α inhibitors.
Das J; Moquin RV; Dyckman AJ; Li T; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Newitt JA; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2010 Dec; 20(23):6886-9. PubMed ID: 21035336
[TBL] [Abstract][Full Text] [Related]
19. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.
Simard JR; Getlik M; Grütter C; Pawar V; Wulfert S; Rabiller M; Rauh D
J Am Chem Soc; 2009 Sep; 131(37):13286-96. PubMed ID: 19572644
[TBL] [Abstract][Full Text] [Related]
20. Targeting the hinge glycine flip and the activation loop: novel approach to potent p38α inhibitors.
Martz KE; Dorn A; Baur B; Schattel V; Goettert MI; Mayer-Wrangowski SC; Rauh D; Laufer SA
J Med Chem; 2012 Sep; 55(17):7862-74. PubMed ID: 22897496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
